

### DISCLAIMER

This presentation includes forward-looking statements. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding the Company's future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements use words like "believe," "plan," "expect," "intend," "will," "would," "anticipate," "estimate," and similar words or expressions in discussions of the Company's future operations, financial performance or the Company's strategies. These statements are based on current expectations or objectives that are inherently uncertain. In light of these uncertainties, and the assumptions underlying the expectations and other forward-looking statements expressed, the forward-looking events and circumstances discussed in the accompanying materials may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, those factors described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recent Form 10-K and Form 10-Q filed with the Securities and Exchange Commission, and similar disclosures in subsequent reports filed with the SEC. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company's expectations regarding changes in regulatory requirements; the Company's ability to interoperate with the electronic health record systems of its customers; the Company's reliance on vendors; the Company's ability to attract and retain key personnel; the competition to attract and retain remote documentation specialists; anticipated trends, growth rates, and challenges in the Company's business and in the markets in which the Company operates; the Company's ability to further penetrate its existing customer base; the Company's ability to protect and enforce its intellectual property protection and the scope and duration of such protection; developments and projections relating to the Company's competitors and the Company's industry, including competing dictation software providers, third-party, non-real time medical note generators and real time medical note documentation services; the impact of current and future laws and regulations; and the impact of the COVID-19 crisis on the Company's business, results of operations and future growth prospects. Past performance is not necessarily indicative of future results. The forward-looking statements will cause the Company's views to change. The Company's views as of the date of this presentation. The Company anticipates that subsequent events and developments will cause the Company's views to change. These forward-lo

This presentation includes information related to market opportunity as well as cost and other estimates obtained from internal analyses and external sources. The internal analyses are based upon management's understanding of market and industry conditions and have not been verified by independent sources. Similarly, the externally sourced information has been obtained from sources the Company believes to be reliable, but the accuracy and completeness of such information cannot be assured. ny of its respective officers, directors, managers, employees, agents, or representatives, undertake to update any of such information or provide additional information as a result of new information or future events or developments.

# BUSINESS OVERVIEW

-X84-0

### A DECADE OF OUTSTANDING GROWTH DUE TO EXCEPTIONAL CAPITAL ALLOCATION




All driven with an initial \$150k investment a decade ago with zero outside capital or credit terms



#### A robust proven business model with a decade of aggressive growth performance


## KEY FINANCIAL HIGHLIGHTS HISTORICAL REVENUE AND MARGINS

Revenue (\$M)




(1) Preliminary 2024 revenue outlook as provided on May 2024





### RECENT FINANCIAL PERFORMANCE QUARTERLY REVENUE



E.C.D. Nasdaq: ECDA Except for 1Q24, 1Q23, 2Q24and 2Q23, revenue numbers are unaudited

### 2Q24 Key Highlights

• 129% revenue increase compared to 2Q23

• Gross margins of 31.8%

· Acquired assets of Brand New Muscle Car to build classic American Muscle Cars, starting with the Ford Mustang

• Agreement with Black Dog Trading to add classic Toyota FJs to product line up

2Q24

### ORGANIC PATH TO \$75M REVENUE & 30%+ GROSS MARGINS

### NORTH LINE - BR

North Production Line Overview

• # Units PA: 64 - \$25m

• Avg selling price Inc. Upgrades: \$390k

### SOUTH LINE - AMC

#### South Production Line Overview

- # Units PA: 70 \$23m
- Avg selling price Inc. Upgrades: \$325k

#### **East Production Line Overview**



### EAST LINE - BC

• # Units PA: 65 - \$24m

• Avg selling price Inc. Upgrades: \$375k



Equity Capitalization Table	Shares
ECD Founders Outside Shareholders Total *Shares Subject to Lock-Up; 82% of the Float	24,000,000 10,100,000 34.100,000 27,650,000


Debt Instruments	Amount	
Convertible Note Due December 2026, priced at prime + 5%	\$15,800,000	


### VALUE DRIVEN BY EXCEPTIONAL UNIT ECONOMICS

Unit-Level Gross Profit By Manufacturer

Brand	GP \$ per unit	Notes
Ferrari	\$123k	Margin through quality & customization
<b>E.C.D.</b> Automotive design	\$96k	Margin through quality & customization
	\$37k	Not mass luxury – Macan Diluted
	\$9k	Lost margin through volume & limited options
gm	\$3k	Targets profit post sale

Source: Tesla Data – The Motley Fool : 10/22/23, Ferrari data – 2023 Annual filing, Porsche - Quarterly Statement, Porsche AG Group January – September 2023, GM data – GM authority, ECD – Gross profit 33% 2024 actual. Net profit 13%





(2) Sales price for base vehicle



- (1) Based on 2023 ECD pricing analysis for Defender models
- (3) Approximate vehicle gross margin

### BRAND NEW MUSCLE CAR ACQUISITION

- Meaningfully expands the total addressable market of ECD
- Unit economics on par with existing
   ECD product portfolio
- On track to deliver product in the second half of 2024





## BLACK DOG TRADERS LICENSING AGREEMENT

- Licensing Agreement to produce branded Toyota FJ SUVs
- Further expands total addressable market
- Ability to increase margins at a luxury price point





# BLACKBRIDGE MOTORS

- Allows ECD to expand within the luxury
   Defender market, increase factory utilization
   and enhance its industry-leading margins
   at a luxury price point with a fully bespoke
   customization package
- Increases market penetration in a capital-efficient manner
- Access to Blackbridge's IP, branding and topof-funnel marketing support in exchange for a fee and royalty per vehicle sale






### THE CLASSIC CAR - ECOSYSTEM TAM

The Classic Car Owner Desires a One Stop White Glove, Trusted & All-Encompassing Automotive Partner Through The Duration Of Ownership





# CREATE IT, BUILD IT, LIVE IT.

THANK

YOU

E.C.D. Auto Design
Scott Wallace, Chairman and CEO

Email: investorrelations@ecdautodesign.com Tel: 407-483-4825 MZ Group Brian M. Prenoveau, CFA

Email: ecda@mzgroup.us Tel: 561-489-5315